These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 7644884)

  • 1. [Analysis of the efficiency of the screening of anti-HVA IgG antibodies before active or passive immunization].
    Arnal Alonso JM; Frisas Clavero O; Garuz Bellido R; Forcen Alonso T
    Rev Sanid Hig Publica (Madr); 1995; 69(1):71-8. PubMed ID: 7644884
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effective analysis of hepatitis A prevention in Ireland.
    Rajan E; Shattock AG; Fielding JF
    Am J Gastroenterol; 2000 Jan; 95(1):223-6. PubMed ID: 10638588
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Critical prevalence of antibodies minimizing vaccination costs for hepatitis A, hepatitis B, varicella, measles and tetanus in adults and adolescents in Catalonia, Spain.
    Plans-Rubió P
    Vaccine; 2004 Sep; 22(29-30):4002-13. PubMed ID: 15364450
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Efficiency of prevaccination screening of anti-HBc in the anti-hepatitis B vaccination programs].
    Navas E; Bayas JM; Taberner JL; Salleras L
    Med Clin (Barc); 1992 Nov; 99(17):641-4. PubMed ID: 1447934
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regional variation in the cost effectiveness of childhood hepatitis A immunization.
    Jacobs RJ; Greenberg DP; Koff RS; Saab S; Meyerhoff AS
    Pediatr Infect Dis J; 2003 Oct; 22(10):904-14. PubMed ID: 14551492
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The prevalence of markers for the hepatitis A and B viruses in the population of Gijón between 6 and 25 years old].
    Suárez A; Navascués CA; García R; Peredo B; Miguel D; Menéndez MT; Saro C; Román F
    Med Clin (Barc); 1996 Apr; 106(13):491-4. PubMed ID: 8992130
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The prevalence and direct costs of pre-immunization testing for hepatitis A in general practice.
    Buckley D; Fahey T; Bevan G
    Br J Gen Pract; 1996 Sep; 46(410):541-2. PubMed ID: 8917876
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High prevalence of hepatitis A virus antibody among Bangladeshi children and young adults warrants pre-immunization screening of antibody in HAV vaccination strategy.
    Ahmed M; Munshi SU; Nessa A; Ullah MS; Tabassum S; Islam MN
    Indian J Med Microbiol; 2009; 27(1):48-50. PubMed ID: 19172060
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatitis A vaccines.
    Shahidah KN
    Med J Malaysia; 2005 Jul; 60 Suppl B():112-5. PubMed ID: 16108190
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of universal toddlers-only hepatitis A virus vaccination program on seropositivity rate in unvaccinated toddlers: evidence for reduced virus circulation in the community.
    Barkai G; Belmaker I; Givon-Lavi N; Dagan R
    Pediatr Infect Dis J; 2009 May; 28(5):391-3. PubMed ID: 19295466
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differences in hepatitis A seroprevalence among geographical regions in Turkey: a need for regional vaccination recommendations.
    Ceyhan M; Yildirim I; Kurt N; Uysal G; Dikici B; Ecevit C; Aydogan A; Koc A; Yasa O; Köseoğlu M; Onal K; Hacimustafaoglu M; Celebi S
    J Viral Hepat; 2008 Oct; 15 Suppl 2():69-72. PubMed ID: 18837839
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Testing for antibody to hepatitis A to decrease the cost of hepatitis A prophylaxis with immune globulin or hepatitis A vaccines.
    Bryan JP; Nelson M
    Arch Intern Med; 1994 Mar; 154(6):663-8. PubMed ID: 8129500
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [A change in the epidemiologic pattern of hepatitis A in Spain].
    Salleras L; Bruguera M; Vidal J; Taberner JL; Plans P; Jiménez de Anta MT; Rodés J
    Med Clin (Barc); 1992 Jun; 99(3):87-9. PubMed ID: 1321318
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Screening policy for travellers from Rotterdam for hepatitis A antibodies prior to eventual immunization: favourable cost-benefit ratio].
    Reintjes R; Bosman A; de Zwart O
    Ned Tijdschr Geneeskd; 1999 Aug; 143(35):1777-80. PubMed ID: 10494329
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of universal childhood hepatitis A vaccination in Chile.
    Valenzuela MT; Jacobs RJ; Arteaga O; Navarrete MS; Meyerhoff AS; Innis BL
    Vaccine; 2005 Jul; 23(32):4110-9. PubMed ID: 15964479
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Chronic hepatitis C and risk for hepatitis A infection].
    Chlabicz S; Grzeszczuk A
    Przegl Epidemiol; 2001; 55(3):281-6. PubMed ID: 11761835
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The prevalence of hepatitis A, B and C viral markers in the population of Gijón between 26 and 65 years old].
    Suárez A; Viejo G; Navascués CA; García R; Díaz G; Saro C; Román FJ
    Gastroenterol Hepatol; 1997; 20(7):347-52. PubMed ID: 9377232
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epidemiology of hepatitis A and hepatitis E infection and their determinants in adult Chinese community in Hong Kong.
    Wong KH; Liu YM; Ng PS; Young BW; Lee SS
    J Med Virol; 2004 Apr; 72(4):538-44. PubMed ID: 14981755
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The efficacy of the prevaccination detection of anti-HAV in hepatitis A vaccination programs].
    Navas E; Bayas JM; Bruguera M; Vidal J; Galí N; Taberner JL; Salleras L
    Med Clin (Barc); 1995 Jul; 105(5):168-71. PubMed ID: 7630228
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of hepatitis A antibodies in schoolchildren in Catalonia (Spain) after the introduction of universal hepatitis A immunization.
    Domínguez A; Bruguera M; Plans P; Costa J; Salleras L
    J Med Virol; 2004 Jun; 73(2):172-6. PubMed ID: 15122789
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.